June 3 (Reuters) - Johnson & Johnson JNJ.N:
JOHNSON & JOHNSON LEADS WITH FIRST PARP INHIBITOR COMBO TO IMPROVE EFFICACY IN PATIENTS WITH HRR-ALTERED MCSPC
JOHNSON & JOHNSON - 50% REDUCTION IN DISEASE PROGRESSION IN BRCA-ALTERED MCSPC
JOHNSON & JOHNSON - PHASE 3 AMPLITUDE STUDY SHOWS AKEEGA DELAYS CANCER PROGRESSION
JOHNSON & JOHNSON - PHASE 3 AMPLITUDE STUDY MEETS PRIMARY ENDPOINT OF RPFS
Source text: ID:nPnb7FvWVa
Further company coverage: JNJ.N
((Reuters.Briefs@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.